Peterson, Bradley S. http://orcid.org/0000-0001-5737-225X
West, Amy E.
Weisz, John R.
Mack, Wendy J.
Kipke, Michele D.
Findling, Robert L.
Mittman, Brian S.
Bansal, Ravi
Piantadosi, Steven
Takata, Glenn
Koebnick, Corinna
Ashen, Ceth
Snowdy, Christopher
Poulsen, Marie
Arora, Bhavana Kumar
Allem, Courtney M.
Perez, Marisa
Marcy, Stephanie N.
Hudson, Bradley O.
Chan, Stephanie H.
Weersing, Robin
Funding for this research was provided by:
Patient-Centered Outcomes Research Institute (PEDS-2019C1-16008)
Article History
Received: 19 April 2021
Accepted: 4 June 2021
First Online: 30 June 2021
Declarations
:
: This study protocol was reviewed and approved under the SMART Institutional Review Board (IRB) mechanism, with Children’s Hospital Los Angeles the designated lead IRB. Parents will provide informed written consent for their child’s participation, and the child will provide informed written assent for both the clinical trial and the ancillary study, which will be obtained by trained study personnel.
: Not applicable.
: Dr. Peterson has received investigator-initiated support from Eli Lilly and Pfizer and has served as a paid consultant to Shire Human Genetic Therapies. He is also President of Evolve Psychiatry Professional Corporation and a paid advisor to Evolve Residential Treatment Centers. Dr. Findling receives or has received research support, acted as a consultant for, and/or has received honoraria from Acadia, Adamas, Aevi, Afecta, Akili, Alkermes, Allergan, American Academy of Child & Adolescent Psychiatry, American Psychiatric Press, Arbor, Axsome, Daiichi-Sankyo, Emelex, Gedeon Richter, Genentech, Idorsia, Intra-Cellular Therapies, Kempharm, Luminopia, Lundbeck, MedAvante-ProPhase, Merck, MJH Life Sciences,NIH, Neurim, Otsuka, PaxMedica, PCORI, Pfizer, Physicians Postgraduate Press, Q BioMed, Receptor Life Sciences, Roche, Sage, Signant Health, Sunovion, Supernus Pharmaceuticals, Syneos, Syneurx, Takeda, Teva, Tris, and Validus. All other authors declare that they have no competing interests.